Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)

Brendan O'Boyle2.83K FollowersFollow5ShareSavePlay(8min)CommentsSummaryCorcept Therapeutics Incorporated receives early FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, transforming its investment narrative.Lifyorli demonstrated a 35% reduction in risk of death and strong tolerability, positioning CORT as a new oncology leader in ovarian cancer.Analyst consensus sees Lifyorli's growth offsetting Korlym's decline, with 2026 sales guidance at $900M–$1B and potential blockbuster expansion.I upgrade CORT to Strong Buy, citing robust clinical data, a de-risked commercialization, and a compelling risk/reward profile post-approval.

Mohamad Faizal Bin Ramli/iStock via Getty Images Just over one month ago, I upgraded Corcept Therapeutics Incorporated (CORT) to Buy following the company's loss in its patent litigation against Teva Pharmaceuticals (TEVA). ThisThis article was written byBrendan O'Boyle2.83K FollowersFollowBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/we have a beneficial long position in the shares of CORT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The author is long shares of CORT but may increase the position with additional purchases or by selling cash-secured puts.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.